Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Steuber

Showing results (191-200 of 209) with videos related to

Pageof 21
Sort By:
The Lancet. Oncology|October 3, 2021
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 studyFred Saad, Eleni Efstathiou, Gerhardt Attard, et al.
Neoplasia (New York, N.Y.)|March 11, 2017
Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate CancersChristoph Burdelski, Michael Fitzner, Claudia Hube-Magg, et al.
BJU International|August 2, 2006
Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validationFelix K-H Chun, Alberto Briganti, Shahrokh F Shariat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2016
The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate CancerMaximilian Lennartz, Sarah Minner, Sophie Brasch, et al.
European Urology Oncology|May 10, 2024
Biochemical Response of <0.1 ng/ml Predicts Therapy-free Survival of Prostate Cancer Patients following Prostate-specific Membrane Antigen-targeted Salvage SurgerySophie Knipper, Flemming Lischewski, Daniel Koehler, et al.
Oncotarget|March 23, 2019
A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancerTill Eichenauer, Mohammad Hussein, Claudia Hube-Magg, et al.
The Journal of Urology|January 16, 2007
Development and external validation of an extended repeat biopsy nomogramFelix K-H Chun, Alberto Briganti, Markus Graefen, et al.
International Journal of Radiation Oncology, Biology, Physics|October 30, 2009
Unilateral prostate cancer cannot be accurately predicted in low-risk patientsHendrik Isbarn, Pierre I Karakiewicz, Susanne Vogel, et al.
World Journal of Urology|November 21, 2019
Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancerSimon Kind, Franziska Büscheck, Doris Höflmayer, et al.
European Urology Oncology|June 4, 2026
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 StudyPhilipp Cornelius Mandel, Mike Wenzel, María Natalia Gandur Quiroga, et al.
Pageof 21

Showing results (191-200 of 209) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|October 3, 2021
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 studyFred Saad, Eleni Efstathiou, Gerhardt Attard, et al.
Neoplasia (New York, N.Y.)|March 11, 2017
Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate CancersChristoph Burdelski, Michael Fitzner, Claudia Hube-Magg, et al.
BJU International|August 2, 2006
Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validationFelix K-H Chun, Alberto Briganti, Shahrokh F Shariat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2016
The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate CancerMaximilian Lennartz, Sarah Minner, Sophie Brasch, et al.
European Urology Oncology|May 10, 2024
Biochemical Response of <0.1 ng/ml Predicts Therapy-free Survival of Prostate Cancer Patients following Prostate-specific Membrane Antigen-targeted Salvage SurgerySophie Knipper, Flemming Lischewski, Daniel Koehler, et al.
Oncotarget|March 23, 2019
A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancerTill Eichenauer, Mohammad Hussein, Claudia Hube-Magg, et al.
The Journal of Urology|January 16, 2007
Development and external validation of an extended repeat biopsy nomogramFelix K-H Chun, Alberto Briganti, Markus Graefen, et al.
International Journal of Radiation Oncology, Biology, Physics|October 30, 2009
Unilateral prostate cancer cannot be accurately predicted in low-risk patientsHendrik Isbarn, Pierre I Karakiewicz, Susanne Vogel, et al.
World Journal of Urology|November 21, 2019
Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancerSimon Kind, Franziska Büscheck, Doris Höflmayer, et al.
European Urology Oncology|June 4, 2026
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 StudyPhilipp Cornelius Mandel, Mike Wenzel, María Natalia Gandur Quiroga, et al.
Pageof 21